Jonas Eriksson

J Cereb Blood Flow Metab 2015 May 4;35(5):766-72. Epub 2015 Feb 4.

Division of Clinical Neurosciences, Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.

Int J Radiat Oncol Biol Phys 2015 Feb 6;91(2):351-9. Epub 2014 Dec 6.

Department of Radiation Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.

Clin Cancer Res 2014 Dec 14;20(24):6389-97. Epub 2014 Oct 14.

Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.

EJNMMI Research 2014, 4:62

EJNMMI Research

Background The serotonin precursor 5-hydroxy-L-[β-11C]tryptophan ([11C]HTP) is in clinical use for localization of neuroendocrine tumors and has been suggested as a proxy marker for pancreatic islet cells. However, degradation by monoamine oxidase-A (MAO-A) reduces retention and the contrast to non-endocrine tissue. Methods A synthesis method was developed for 5-hydroxy-L-[β-11C2H]tryptophan ([11C]DHTP), an isotopologue of [11C]HTP, labeled with 11C and 2H at the β-position adjacent to the carbon involved in MAO-A decarboxylation. MAO-A-mediated degradation of [11C]DHTP was evaluated and compared to non-deuterated [11C]HTP. Results [11C]DHTP was synthesized with a radiochemical purity of >98%, radioactivity of 620 ± 190 MBq, and deuterium (2H or 2H2) incorporation at the β-position of 22% ±5%. Retention and resistance to MAO-A-mediated degradation of [11C]DHTP were increased in cells but not in non-human primate pancreas. Conclusions Partial deuteration of the β-position yields improved resistance to MAO-A-mediated degradation in vitro but not in vivo.

Neuropharmacology 2014 Oct 28;85:104-12. Epub 2014 May 28.

Institute of Pharmacology, Toxicology & Pharmacy, Ludwig-Maximilians-University, Munich, Germany. Electronic address:

J Nucl Med 2013 Dec 3;54(12):2101-3. Epub 2013 Oct 3.

Departments of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.

Radiother Oncol 2013 Oct 14;109(1):58-64. Epub 2013 Sep 14.

Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands. Electronic address:

Clin Cancer Res 2013 Aug 25;19(15):4163-73. Epub 2013 Apr 25.

Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.

Nucl Med Biol 2013 Aug 1;40(6):764-75. Epub 2013 Jul 1.

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Nucl Med Biol 2013 May 20;40(4):488-97. Epub 2013 Mar 20.

Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.

PLoS One 2012 31;7(10):e48430. Epub 2012 Oct 31.

Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands.

ACS Chem Neurosci 2013 Feb 4;4(2):225-37. Epub 2012 Dec 4.

Department of Public Health and Caring Sciences, Uppsala University, Rudbecklaboratoriet, 751 85 Uppsala, Sweden.

J Nucl Med 2012 Dec 9;53(12):1974-83. Epub 2012 Nov 9.

Division of Pharmacology, LACDR, Leiden University, Leiden, The Netherlands.

EJNMMI Res 2012 Oct 16;2(1):57. Epub 2012 Oct 16.

Department of Neurology and Alzheimer Center, VU University Medical Center, P,O, Box 7057, Amsterdam, 1007 MB, The Netherlands.

EJNMMI Res 2012 Jul 2;2(1):36. Epub 2012 Jul 2.

Department of Nuclear Medicine & PET Research, Radionuclide Centre, VU University Medical Center, P,O, box 7057, Amsterdam 1081, HV, The Netherlands.

Nucl Med Biol 2012 May 5;39(4):530-9. Epub 2012 Jan 5.

Department of Nuclear Medicine & PET Research, VU University Medical Center, Amsterdam, the Netherlands.

J Label Compd Radiopharm, 55: 223–228

Journal of Labelled Compounds and Radiopharmaceuticals

Transition metal mediated carbonylation with [11C]CO has proven a useful method to label a wide array of compounds in the carbonyl position. However, the general use in radiopharmaceutical synthesis has been hampered by the low solubility of carbon monoxide in most solvents and the resulting challenge to confine [11C]CO in low volume reaction vessels. This paper introduces a method that utilises xenon to transfer pre-concentrated [11C]CO to a sealed disposable glass vial containing carbonylation reagents. The high solubility of xenon in the organic solvent made it possible to confine the [11C]CO without utilising a pressure autoclave or chemical trapping additives. The utility of the method in 11C-carbonylation was investigated by conducting three model reactions, where [11C-carbonyl]N-benzylbenzamide, [11C-carbonyl]triclocarban and [11C-carbonyl]methyl nicotinate were afforded in decay corrected radiochemical yields of 71 ± 6%, 42 ± 15% and 29 ± 10%, respectively. These promising results and the straight forward technical implementation suggest that 11C-cabonylation can become a viable mean to provide labelled carbonyl functionalities in routine radiopharmaceutical synthesis. Compounds labelled with short lived positron emitters are used in Positron Emission Tomography, a molecular imaging technology with applications in clinical diagnostics, clinical research and basic biomedical research

EJNMMI Res 2012 Mar 28;2:12. Epub 2012 Mar 28.

Division of Pharmacology, LACDR, Leiden University, PO Box 9502, Leiden, 2300 RA, The Netherlands.

Cancer Cell 2012 Jan;21(1):82-91

Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands.

BMC Med Imaging 2007 Jul 30;7. Epub 2007 Jul 30.

Uppsala Imanet, GE Healthcare, Uppsala, Sweden.

Eur. J. Org. Chem., 2007: 455–461

European Journal of Organic Chemistry

Two methods are presented for the synthesis of acrylamides labelled with 11C (β+, t1/2 = 20.4 min) and 13C in the carbonyl position. In the first method, [1-11C]acrylic acid is synthesised from [11C]carbon monoxide by palladium-mediated hydroxycarbonylation of acetylene. The labelled carboxylic acid is converted into the acyl chloride and subsequently treated with amine to yield N-benzyl[carbonyl-11C]acrylamide. The second method utilizes [11C]carbon monoxide in a palladium-mediated carbonylative cross-coupling of vinyl halides and amines. A higher radiochemical yield is achieved with the latter method and the amount of amine needed is decreased to 1/20. The 11C-labelled acrylamides were isolated in up to 81 % decay-corrected radiochemical yield. Starting from 10 ± 0.5 GBq of [11C]carbon monoxide, N-benzyl[carbonyl-11C]acrylamide was obtained in 4 min with a specific radioactivity of 330 ± 4 GBq μmol–1. Co-labelling with 11C and 13C enabled confirmation of the labelled position by 13C NMR spectroscopy. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)

J Label Compd Radiopharm, 49: 1177–1186

Journal of Labelled Compounds and Radiopharmaceuticals

A method and an apparatus for preparing [11C]methyl iodide from [11C]methane and iodine in a single pass through a non-thermal plasma reactor has been developed. The plasma was created by applying high voltage (400 V/31 kHz) to electrodes in a stream of helium gas at reduced pressure. The [11C]methane used in the experiments was produced from [11C]carbon dioxide via reduction with hydrogen over nickel. [11C]methyl iodide was obtained with a specific radioactivity of 412 ± 32 GBq/µmol within 6 min from approximately 24 GBq of [11C]carbon dioxide. The decay corrected radiochemical yield was 13 ± 3% based on [11C]carbon dioxide at start of synthesis. [11C]Flumazenil was synthesized via a N-alkylation with the prepared [11C]methyl iodide. Copyright © 2006 John Wiley & Sons, Ltd.

J Label Compd Radiopharm, 49: 1105–1116

Journal of Labelled Compounds and Radiopharmaceuticals

A method to prepare [1-11C]propyl iodide and [1-11C]butyl iodide from [11C]carbon monoxide via a three step reaction sequence is presented. Palladium mediated formylation of ethene with [11C]carbon monoxide and hydrogen gave [1-11C]propionaldehyde and [1-11C]propionic acid. The carbonylation products were reduced and subsequently converted to [1-11C]propyl iodide. Labelled propyl iodide was obtained in 58±4% decay corrected radiochemical yield and with a specific radioactivity of 270±33 GBq/µmol within 15 min from approximately 12 GBq of [11C]carbon monoxide. The position of the label was confirmed by 13C-labelling and 13C-NMR analysis. [1-11C]Butyl iodide was obtained correspondingly from propene and approximately 8 GBq of [11C]carbon monoxide, in 34±2% decay corrected radiochemical yield and with a specific radioactivity of 146±20 GBq/µmol. The alkyl iodides were used in model reactions to synthesize [O-propyl-1-11C]propyl and [O-butyl-1-11C]butyl benzoate. Propyl and butyl analogues of etomidate, a β-11-hydroxylase inhibitor, were also synthesized. Copyright © 2006 John Wiley & Sons, Ltd.

J Org Chem 2006 Jun;71(13):4742-7

Department of Chemistry and Biochemistry, Laurentian University, Sudbury, Ontario, P3E 2C6, Canada.

J Label Compd Radiopharm, 47: 723–731

Journal of Labelled Compounds and Radiopharmaceuticals

A method is presented for preparing [1-11C]ethyl iodide from [11C]carbon monoxide. The method utilizes methyl iodide and [11C]carbon monoxide in a palladium-mediated carbonylation reaction to form a mixture of [1-11C]acetic acid and [1-11C]methyl acetate. The acetates are reduced to [1-11C]ethanol and subsequently converted to [1-11C]ethyl iodide. The synthesis time was 20 min and the decay-corrected radiochemical yield of [1-11C]ethyl iodide was 55 ± 5%. The position of the label was confirmed by 13C-labelling and 13C-NMR analysis. [1-11C]Ethyl iodide was used in two model reactions, an O-alkylation and an N-alkylation. Starting with approximately 2.5 GBq of [11C]carbon monoxide, the isolated decay-corrected radiochemical yields for the ester and the amine derivatives were 45 ± 0.5% and 25 ± 2%, respectively, based on [11C]carbon monoxide. Starting with 10 GBq of [11C]carbon monoxide, 0.55 GBq of the labelled ester was isolated within 40 min with a specific radioactivity of 36 GBq/µmol. Copyright © 2004 John Wiley & Sons, Ltd.

Chemistry 2003 Jun;9(12):2696-709

Department of Chemistry and Biochemistry, Laurentian University Sudbury, Ontario P3E 2C6, Canada.